ROIV Form 144: 104,940 shares planned sale on NASDAQ

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) filed a Notice of Proposed Sale under Rule 144 reporting the planned sale of 104,940 common shares (approximately 104,940 shares) with an aggregate market value of $1,710,040.33, scheduled for 10/09/2025 on NASDAQ. The filing states these shares were acquired via an options exercise on 10/09/2025 tied to a grant dated 03/26/2020, with payment by wire. The filer identifies prior sales by the same person totaling multiple transactions between 07/21/2025 and 10/08/2025, including several multi‑hundred‑thousand share disposals and gross proceeds listed per trade. The notice certifies the signer has no undisclosed material adverse information.

Positive

• Rule 144 disclosure filed, showing procedural compliance
• Broker and exchange specified: Rockefeller Financial LLC and NASDAQ
• Acquisition and payment method disclosed (options exercise; wire)

Negative

• Substantial insider selling: multiple transactions totaling >1.5M shares since 07/21/2025
• Concentrated recent sales: large disposals on 09/19/2025–09/23/2025
• Planned sale of 104,940 shares on 10/09/2025 adds near‑term supply

Insights

Insider Transactions Analyst

Insider executed option exercise then disclosed a planned Rule 144 sale.

The record shows an options exercise created 104,940 shares on 10/09/2025

The filer has a history of large disposals across 07/21/2025–10/08/2025; monitor outstanding share count and potential dilution impact in the near term.

Securities Compliance Counsel

The filing documents Rule 144 compliance and representations about material nonpublic information.

The notice specifies trade mechanics (broker, exchange, wire payment) and aggregates prior sales with gross proceeds disclosed—elements required for transparency under Rule 144.

Investors and compliance teams should note the dates and volumes of recent transactions for reporting timelines and aggregation rules through 10/09/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	104940	1710040.33	682881743	10/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	10/09/2025	Options Exercise - Grant Date 03/26/2020	Roivant Sciences Ltd.			104940	10/09/2025	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common shares	08/20/2025	100000	1172120.12
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Shares	07/21/2025	100000	1151941.91
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Shares	09/19/2025	683818	10220412.21
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	09/22/2025	316182	4741054.24
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	09/22/2025	100000	1501338.85
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	09/23/2025	611000	9061130.00
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Shares	10/06/2025	171396	2800364.71
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	10/07/2025	355161	5734289.35
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	10/08/2025	138602	2244797.15

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Roivant (ROIV) Form 144 disclose?

It discloses a proposed sale of 104,940 common shares valued at $1,710,040.33, with sale date 10/09/2025 on NASDAQ.

How were the 104,940 shares acquired for the ROIV sale?

The shares were acquired by options exercise on 10/09/2025, from a grant dated 03/26/2020.

Who is the broker handling the ROIV sale?

The filing lists Rockefeller Financial LLC, 45 Rockefeller Plaza, Floor 5, New York.

Has the filer recently sold other ROIV shares?

Yes. Multiple sales between 07/21/2025 and 10/08/2025, including trades of 100,000, 683,818, and 611,000 shares with gross proceeds reported per trade.

Does the filing state any undisclosed material information?

The signer represents they do not know any material adverse information not publicly disclosed, per the certification in the notice.